Crescita Therapeutics Inc. (CTX.TO)
CAD 0.57
(1.79%)
CAD 0.57
(1.79%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.77 Million CAD | -21.82% |
| 2022 | 7.38 Million CAD | -12.02% |
| 2021 | 8.39 Million CAD | 47.37% |
| 2020 | 5.69 Million CAD | -0.54% |
| 2019 | 5.72 Million CAD | -33.06% |
| 2018 | 8.55 Million CAD | -9.52% |
| 2017 | 9.45 Million CAD | -41.65% |
| 2016 | 16.21 Million CAD | 255.95% |
| 2015 | 4.55 Million CAD | 21.86% |
| 2014 | 3.73 Million CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 5.75 Million CAD | -2.84% |
| 2024 Q1 | 5.92 Million CAD | 2.58% |
| 2023 FY | 5.77 Million CAD | -21.82% |
| 2023 Q1 | 6.99 Million CAD | -5.36% |
| 2023 Q2 | 5.93 Million CAD | -15.07% |
| 2023 Q3 | 6.25 Million CAD | 5.36% |
| 2023 Q4 | 5.77 Million CAD | -7.67% |
| 2022 Q3 | 7.73 Million CAD | -1.65% |
| 2022 Q1 | 9.39 Million CAD | 11.84% |
| 2022 FY | 7.38 Million CAD | -12.02% |
| 2022 Q2 | 7.86 Million CAD | -16.25% |
| 2022 Q4 | 7.38 Million CAD | -4.49% |
| 2021 Q1 | 7.97 Million CAD | 39.93% |
| 2021 Q4 | 8.39 Million CAD | -1.41% |
| 2021 Q3 | 8.51 Million CAD | 10.91% |
| 2021 Q2 | 7.67 Million CAD | -3.69% |
| 2021 FY | 8.39 Million CAD | 47.37% |
| 2020 Q2 | 5.92 Million CAD | -1.38% |
| 2020 Q1 | 6.01 Million CAD | 4.9% |
| 2020 Q4 | 5.69 Million CAD | -5.11% |
| 2020 Q3 | 6 Million CAD | 1.32% |
| 2020 FY | 5.69 Million CAD | -0.54% |
| 2019 Q4 | 5.72 Million CAD | -47.53% |
| 2019 Q2 | 9.86 Million CAD | 2.99% |
| 2019 FY | 5.72 Million CAD | -33.06% |
| 2019 Q1 | 9.57 Million CAD | 11.88% |
| 2019 Q3 | 10.91 Million CAD | 10.72% |
| 2018 Q1 | 9.81 Million CAD | 3.79% |
| 2018 FY | 8.55 Million CAD | -9.52% |
| 2018 Q4 | 8.55 Million CAD | -1.73% |
| 2018 Q3 | 8.7 Million CAD | 6.22% |
| 2018 Q2 | 8.19 Million CAD | -16.47% |
| 2017 Q3 | 9.93 Million CAD | -24.45% |
| 2017 Q2 | 13.14 Million CAD | -12.98% |
| 2017 FY | 9.45 Million CAD | -41.65% |
| 2017 Q1 | 15.1 Million CAD | -6.8% |
| 2017 Q4 | 9.45 Million CAD | -4.77% |
| 2016 Q1 | 3.6 Million CAD | -20.82% |
| 2016 Q4 | 16.21 Million CAD | -16.23% |
| 2016 Q3 | 19.35 Million CAD | 471.3% |
| 2016 Q2 | 3.38 Million CAD | -6.07% |
| 2016 FY | 16.21 Million CAD | 255.95% |
| 2015 FY | 4.55 Million CAD | 21.86% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 Q4 | 4.55 Million CAD | 0.0% |
| 2014 FY | 3.73 Million CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aurora Cannabis Inc. | 236.8 Million CAD | 97.561% |
| Avicanna Inc. | 13.99 Million CAD | 58.74% |
| Avant Brands Inc. | 33.22 Million CAD | 82.615% |
| Cardiol Therapeutics Inc. | 8.45 Million CAD | 31.677% |
| Knight Therapeutics Inc. | 198.62 Million CAD | 97.092% |
| MediPharm Labs Corp. | 10.93 Million CAD | 47.164% |
| OrganiGram Holdings Inc. | 26.83 Million CAD | 78.473% |
| Canopy Growth Corporation | 799.82 Million CAD | 99.278% |
| Willow Biosciences Inc. | 3.23 Million CAD | -78.437% |
| Auxly Cannabis Group Inc. | 210.85 Million CAD | 97.261% |